Cigna Group (CI) has come under closer investor scrutiny after recent share price moves, with the stock declining 1.9% over the past day and 4.4% over the past week, while longer-term returns remain mixed.

Stepping back from the latest pullback, Cigna Group’s 1 year total shareholder return, including dividends, is down 4.33%. In comparison, the 5 year total shareholder return of 37.43% reflects a more patient reward profile and suggests recent momentum has faded relative to longer holding periods.

If Cigna Group’s recent moves have you reassessing your healthcare exposure, this could be a good moment to see what else is available through our healthcare focused screener 41 healthcare AI stocks

After Cigna Group’s pullback, the stock now sits at $284.85 against an analyst price target of about $340.92 and an intrinsic estimate implying an even larger gap, so the question is where fair value really sits between those anchors.

Most Popular Narrative: 16.4% Undervalued

On the most followed narrative, Cigna Group’s fair value of $340.92 sits well above the last close at $284.85, putting the current pullback in a different light.

Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent; the double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth.

Curious what sits behind that fair value for Cigna Group? The narrative leans heavily on measured revenue growth, modest margin expansion, and a future earnings multiple that assumes investors keep paying up for this business model.

Result: Fair Value of $340.92 (UNDERVALUED)

However, Cigna Group’s heavy dependence on the Evernorth PBM model and ongoing regulatory scrutiny around pricing and billing could weaken this undervalued narrative.

Next Steps

With mixed signals around Cigna Group, do you want a clearer picture or just the headlines? Move quickly, review both the downside and upside, and weigh the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cigna Group?

If Cigna Group has you rethinking your next move, do not stop here. Broaden your watchlist with a few focused stock ideas tailored to different goals.

• Target potential mispricing by scanning companies that combine solid fundamentals with room for improvement using the 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that feature reliable, higher-yield payouts through the 7 dividend fortresses.
• Limit downside risk by concentrating on companies with more resilient profiles using the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.